The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis and other immune-inflammatory rheumatic diseases pose significant global health challenges.
• Tumour necrosis factor (TNF) plays a key role in the pathogenesis of these conditions.
• Anti-TNF therapies have emerged as a cornerstone treatment for these diseases.

Purpose of the Study:

• To review the progress in anti-TNF therapy for immune-inflammatory rheumatic diseases over the past five years.
• To elucidate the scope, limitations, efficacy, safety, and durability of anti-TNF agents.
• To identify future research directions and unmet patient needs.

Main Methods:

• Review of accumulating knowledge and personal perspective on anti-TNF therapy.
• Analysis of clinical data regarding efficacy, safety, and long-term outcomes.
• Assessment of patient and community needs in the context of chronic rheumatic diseases.

Main Results:

• Significant advancements have been made in understanding the efficacy and safety profiles of anti-TNF therapies.
• The limitations and durability of current anti-TNF treatments are becoming clearer.
• Unmet needs in managing chronic immune-inflammatory rheumatic diseases have been identified.

Conclusions:

• Anti-TNF therapies have transformed the management of rheumatoid arthritis and related conditions.
• Further research is needed to develop more cost-effective and comprehensive treatment strategies.
• Future therapeutics should aim to not only halt disease progression but also reverse its long-term consequences and improve quality of life.